Publications by authors named "Andre Pélegrin"

85Publications

Multimodal CEA-Targeted Image-Guided Colorectal Cancer Surgery using In-Labeled SGM-101.

Clin Cancer Res 2020 Nov 8;26(22):5934-5942. Epub 2020 Sep 8.

Department of Radiology, Nuclear Medicine & Anatomy, Radboud University Medical Center, Nijmegen, Gelderland, the Netherlands.

View Article and Find Full Text PDF
November 2020

Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody-dependent HER4 intracellular domain trafficking.

Cancer Sci 2020 Jul 8;111(7):2508-2525. Epub 2020 Jun 8.

Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), Montpellier, France.

View Article and Find Full Text PDF
July 2020

[Players from the program "Investments for the Future": MAbImprove MabEx].

Med Sci (Paris) 2019 Dec 6;35(12):1204-1205. Epub 2020 Jan 6.

EA7501, Université de Tours, Tours, France - CHU de Tours, Tours, France.

View Article and Find Full Text PDF
December 2019

[Antibodies, tools of choice for fluorescence-guided surgery].

Med Sci (Paris) 2019 Dec 6;35(12):1066-1071. Epub 2020 Jan 6.

SurgiMAb, 10 Parc Club du Millénaire, 1025 avenue Henri Becquerel, 34000 Montpellier, France.

View Article and Find Full Text PDF
December 2019

[Radioimmunotherapy: the reasons for confidential clinical use and hope for development].

Med Sci (Paris) 2019 Dec 6;35(12):1062-1065. Epub 2020 Jan 6.

IRCM, Institut de Recherche en Cancérologie de Montpellier, Inserm U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier, F-34298, France.

View Article and Find Full Text PDF
December 2019

[A word from the coordinators].

Med Sci (Paris) 2019 Dec 6;35(12):923. Epub 2020 Jan 6.

Coordinateur du LabEx MabImprove (PIA), et du programme Biomédicaments (Région Centre-Val de Loire), EA7501, Université de Tours, 37032 Tours Cedex, France CHRU de Tours, 37032 Tours Cedex, France.

View Article and Find Full Text PDF
December 2019

ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells.

Cell Commun Signal 2019 08 23;17(1):106. Epub 2019 Aug 23.

Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), F-34298, Montpellier, France.

View Article and Find Full Text PDF
August 2019

Targets for MAbs: innovative approaches for their discovery & validation, LabEx MAbImprove 6 antibody industrial symposium, June 25-26, 2018, Montpellier, France.

MAbs 2019 07 16;11(5):812-825. Epub 2019 May 16.

a IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194 , Université de Montpellier, Institut régional du Cancer de Montpellier , Montpellier , France.

View Article and Find Full Text PDF
July 2019

An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer.

Int J Cancer 2019 10 1;145(7):1838-1851. Epub 2019 Apr 1.

Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), 34298, Montpellier, France.

View Article and Find Full Text PDF
October 2019

SGM-101: An innovative near-infrared dye-antibody conjugate that targets CEA for fluorescence-guided surgery.

Surg Oncol 2017 Jun 9;26(2):153-162. Epub 2017 Mar 9.

Institut régional du Cancer de Montpellier, ICM, Montpellier, F-34298, France; IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France; INSERM, U1194, Montpellier, F-34298, France; Université de Montpellier, Montpellier, F-34298, France. Electronic address:

View Article and Find Full Text PDF
June 2017

T lymphocytes to predict radiation-induced late effects in normal tissues.

Expert Rev Mol Diagn 2017 02 22;17(2):119-127. Epub 2016 Dec 22.

a Immunotargeting and Radiobiology in Oncology , IRCM, Institut de Recherche en Cancérologie de Montpellier , Montpellier , France.

View Article and Find Full Text PDF
February 2017

Autocrine Secretion of Progastrin Promotes the Survival and Self-Renewal of Colon Cancer Stem-like Cells.

Cancer Res 2016 06 4;76(12):3618-28. Epub 2016 May 4.

CNRS, UMR-5203, Institut de Génomique Fonctionnelle, Montpellier, France. INSERM, U661, Montpellier, France. Universités de Montpellier 1 & 2, UMR-5203, Montpellier, France. Department of Pathology, The University of Melbourne, Parkville, Victoria, Australia.

View Article and Find Full Text PDF
June 2016

Neutralization of KIT Oncogenic Signaling in Leukemia with Antibodies Targeting KIT Membrane Proximal Domain 5.

Mol Cancer Ther 2015 Nov 10;14(11):2595-605. Epub 2015 Sep 10.

IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France. INSERM, U1194, Montpellier, France. Université de Montpellier, Montpellier, France. Institut Régional du Cancer de Montpellier, Montpellier, France.

View Article and Find Full Text PDF
November 2015

[The HER3/ERBB3 receptor: the dark side of the ERBB planet].

Med Sci (Paris) 2015 May 9;31(5):465-8. Epub 2015 Jun 9.

IRCM, institut de recherche en cancérologie de Montpellier, 208, rue des Apothicaires, F-34298, Montpellier, France - Inserm U1194, F-34298, France - Université de Montpellier, Montpellier, F-34090, Montpellier, France - Institut régional du cancer de Montpellier, F-34298, Montpellier, France.

View Article and Find Full Text PDF
May 2015

Late side-effects after curative intent radiotherapy: Identification of hypersensitive patients for personalized strategy.

Crit Rev Oncol Hematol 2015 Mar 22;93(3):312-9. Epub 2014 Nov 22.

University of Montpellier I, Montpellier, France; Institut de Recherche en Cancérologie de Montpellier, Montpellier, France; Institut régional du Cancer de Montpellier (ICM) - Val d'Aurelle, Department of Radiotherapy, Montpellier, France.

View Article and Find Full Text PDF
March 2015

HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models.

Oncotarget 2014 Aug;5(16):7138-48

IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France; INSERM, Unit 896, Montpellier, F-34298, France; Université Montpellier1, Montpellier, F-34298, France; ICM, Montpellier, France.

View Article and Find Full Text PDF
August 2014

MAbImprove: a French "Laboratoire d'excellence" (LabEx) dedicated to therapeutic antibodies.

MAbs 2014 Jul-Aug;6(4):803-4. Epub 2014 May 16.

Université François Rabelais de Tours; CNRS, UMR 7292; Tours, France; CHRU de Tours; Service d'immunologie; Tours, France.

View Article and Find Full Text PDF
February 2015

DNA damage-centered signaling pathways are effectively activated during low dose-rate Auger radioimmunotherapy.

Nucl Med Biol 2014 May 6;41 Suppl:e75-83. Epub 2014 Feb 6.

IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France; INSERM, U896, Montpellier, F-34298, France; Université Montpellier 1, Montpellier, F-34298, France; Institut régional de Cancérologie de Montpellier, Montpellier, F-34298, France. Electronic address:

View Article and Find Full Text PDF
May 2014

Peptides in receptor-mediated radiotherapy: from design to the clinical application in cancers.

Front Oncol 2013 Sep 25;3:247. Epub 2013 Sep 25.

Institut de Recherche en Cancérologie de Montpellier , Montpellier , France ; INSERM, U896 , Montpellier , France ; Université Montpellier 1 , Montpellier , France ; Institut Régional du Cancer Montpellier , Montpellier , France.

View Article and Find Full Text PDF
September 2013

General overview of radioimmunotherapy of solid tumors.

Immunotherapy 2013 May;5(5):467-87

IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France.

View Article and Find Full Text PDF
May 2013

Clinical radioimmunotherapy--the role of radiobiology.

Nat Rev Clin Oncol 2011 Nov 8;8(12):720-34. Epub 2011 Nov 8.

Direction de la Radioprotection de l'Homme, Institut de Radioprotection et de Sûreté Nucléaire, Fontenay-aux-Roses, F-92262, France.

View Article and Find Full Text PDF
November 2011

CD4 ligation excludes the Carma1-Bcl10-MALT1 complex from GM1-positive membrane rafts in CD3/CD28 activated T cells.

Cell Immunol 2011 29;270(1):40-6. Epub 2011 Mar 29.

IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier F-34298, France.

View Article and Find Full Text PDF
October 2011

Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice.

Breast Cancer Res 2011 Feb 4;13(1):R17. Epub 2011 Feb 4.

IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U896, Université Montpellier1, CRLC Val d'Aurelle Paul Lamarque, 208 rue des Apothicaires, Montpellier, F-34298, France.

View Article and Find Full Text PDF
February 2011

Anti-HER2 vaccines: new prospects for breast cancer therapy.

Cancer Immunol Immunother 2010 Sep 8;59(9):1295-312. Epub 2010 Jun 8.

IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U896, Université Montpellier1, Montpellier, France.

View Article and Find Full Text PDF
September 2010

Cyclization of peptides through a urea bond: application to the Arg-Gly-Asp tripeptide.

Chembiochem 2010 May;11(8):1083-92

Institut de Recherche en Cancérologie de Montpellier, Université Montpellier1, Montpellier, France.

View Article and Find Full Text PDF
May 2010

Symplekin promotes tumorigenicity by up-regulating claudin-2 expression.

Proc Natl Acad Sci U S A 2010 Feb 25;107(6):2628-33. Epub 2010 Jan 25.

Institut de Génomique Fonctionnelle, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5203, Institut National de la Santé et de la Recherche Médicale U661, and Université Montpellier 1 and 2, Montpellier F-34094, France.

View Article and Find Full Text PDF
February 2010

[Bispecific antibodies: what future?].

Med Sci (Paris) 2009 Dec;25(12):1155-8

Institut de recherche en cancérologie de Montpellier (IRCM), Montpellier, F-34298, France ; Inserm U896, Montpellier, F-34298, France.

View Article and Find Full Text PDF
December 2009

A llama single domain anti-idiotypic antibody mimicking HER2 as a vaccine: Immunogenicity and efficacy.

Vaccine 2009 Jul 11;27(35):4826-33. Epub 2009 Jun 11.

IRCM (Institut de Recherche en Cancérologie de Montpellier), INSERM U896, Université Montpellier 1, CRLC Val d'Aurelle Paul Lamarque, Montpellier Cedex 5, France.

View Article and Find Full Text PDF
July 2009

Single nucleotide polymorphisms, apoptosis, and the development of severe late adverse effects after radiotherapy.

Clin Cancer Res 2008 Oct;14(19):6284-8

INSERM U896, Institut de Recherche en Cancérologie de Montpellier, Department of Radiation Oncology, CRLC Val d'Aurelle-Paul Lamarque, Montpellier, France.

View Article and Find Full Text PDF
October 2008

Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional protein.

Protein Eng Des Sel 2008 Nov 11;21(11):665-72. Epub 2008 Sep 11.

IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U896, Université Montpellier1, Montpellier F-34298, France.

View Article and Find Full Text PDF
November 2008

Cell-penetrating and cell-targeting peptides in drug delivery.

Biochim Biophys Acta 2008 Dec 9;1786(2):126-38. Epub 2008 Apr 9.

IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France.

View Article and Find Full Text PDF
December 2008

Radiocurability by targeting tumor necrosis factor-alpha using a bispecific antibody in carcinoembryonic antigen transgenic mice.

Int J Radiat Oncol Biol Phys 2007 Nov;69(4):1231-7

INSERM, Centre de Recherche en Cancérologie de Montpellier, Université de Montpellier, CRLC Val d'Aurelle-Paul Lamarque, Montpellier, France.

View Article and Find Full Text PDF
November 2007

[Combination of anti-EGFR and anti-HER2 antibodies: hope in pancreatic cancer treatment].

Bull Cancer 2007 Oct;94(10):860-2

Centre de recherche en cancérologie de Montpellier (CRCM), Inserm U860 Immunociblage et radiobiologie en oncologie, Université Montpellier 1.

View Article and Find Full Text PDF
October 2007

MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells.

Clin Cancer Res 2005 Oct;11(20):7516-22

INSERM, EMI0227, Centre de Recherche en Cancérologie de Montpellier, Centre Régional de Lutte contre le Cancer Val d'Aurelle-Paul Lamarque, Montpellier, France.

View Article and Find Full Text PDF
October 2005

Letrozole sensitizes breast cancer cells to ionizing radiation.

Breast Cancer Res 2005 7;7(1):R156-63. Epub 2004 Dec 7.

Department of Radiation Oncology, CRLC Val d'Aurelle, Montpellier, France.

View Article and Find Full Text PDF
January 2006

[Bioluminescent imaging: applications to cancerology and endocrinology].

J Soc Biol 2004 ;198(2):157-61

INSERM Unité 540, Endocrinologie Moléculaire et Cellulaire des Cancers, 60, rue de Navacelles, 34090 Montpellier.

View Article and Find Full Text PDF
December 2004

[Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials].

Bull Cancer 2003 Nov;90 Spec No:S202-12

Département d'oncologie-radiothérapie, Laboratoire d'immunociblage des tumeurs et ingénierie des anticorps, EMI 0227, CRLC Val-d'Aurelle-Paul-Lamarque, 34298 Montpellier.

View Article and Find Full Text PDF
November 2003